This study seeks to examine the efficacy of hydrocortisone administration in the augmentation of the therapeutic effects of Prolonged Exposure (PE) therapy, an empirically tested treatment shown to be effective in the the treatment of posttraumatic stress disorder (PTSD). The augmentation builds on both the translation of neuroscience findings demonstrating the effects of glucocorticoids (GCs) on learning, and on empirical clinical findings from other investigators demonstrating beneficial effects of GCs in reducing traumatic memories in trauma-exposed persons.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
11
10 weekly sessions
30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
placebo
James J. Peters Veterans Affairs Medical Center
The Bronx, New York, United States
Change in PTSD symptom severity as assessed by the Clinician Administered PTSD Scale (CAPS)
Time frame: Baseline (Week 0), endpoint (week 11)
Cognitive performance (learning and retention in an episodic memory task, attention and working memory)
Time frame: Baseline (Week 0), endpoint (week 11)
Other measures of clinical outcome, psychological state and functioning
Time frame: Approximately 1 week prior to starting therapy (Week 0) and approximately 1 week after completing 10 weeks of therapy (week 11)
Biological measures associated with PTSD severity
Time frame: Approximately 1 week prior to starting therapy (Week 0) and approximately 1 week after completing 10 weeks of therapy (week 11)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.